Okugen (NASDAQ:OCGN) said Interim data from a phase 2/3 trial of Covaxin, developed by Indian Bharat Biotech, were published in a journal and showed that the vaccine against COVID-19 showed efficacy and an excellent response in children than is observed in adults.
Data from the study, which included 526 children aged two to 18, were published in Lancet infectious diseasesOkugen (OCGN) said in a press release on June 21.
Two doses of the vaccine were given at 28-day intervals in three groups: two to six years, six to 12 years, and 12 to 18 years.
Okugen (OCGN) said that the data showed that the same dose was effective in both pediatrics and adults.
The company added that the pediatric study had no serious adverse events, deaths or seizures due to an adverse event, including no cases of Guillain-Barré syndrome (a disorder in which the immune system attacks the nerves), blood clot events, inflammation. of heart muscle or other adverse events.
“We have now achieved our goal of developing a safe and effective vaccine against COVID-19 for adults and children, for primary immunization and booster doses, making COVAXIN a universal vaccine,” said Krishna Ella, Chairman and Managing Director of Bharat Biotech.
Okugen (OCGN) has marketing rights in North America for Covaxin and the vaccine is in a clinical trial by a US company for use in adults 18 years of age and older.
The Covaxin vaccine is approved for emergency use in Mexico for adults.
OCGN + 3.70% $ 2.24 presale on June 21